Novartis Enters into a Four-Year Collaboration with Orionis Biosciences to Tackle Intractable Disease Targets

Shots:

• Orionis to receive research funding, convertible notes, clinical milestones along with royalties while Novartis gets access to Orionis’ Allo-Glue technology platform for designing novel therapies like protein degraders across multiple therapeutic areas
• The collaboration will combine Novartis’ expertise in drug discovery and development with Orionis’ innovative technologies for identifying and prioritizing new targets at a genome-wide scale
• Allo-Glue molecules are the class of allosterically acting small molecules, which act by altering the function of intracellular proteins engaging in molecular interactions and modulating disease target proteins

Click here to­ read full press release/ article | Ref: Businesswire  | Image: StraitTimes